Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention

References

• Jaff MR, Cahill KE, Yu AP, et al. Clinical outcomes and medical care costs among medicare beneficiaries receiving therapy for peripheral arterial disease. Ann Vasc Surg. 2010;24(5):577–587.
   PubMed Web of Science ®Google Scholar
• Baser O, Verpillat P, Gabriel S, et al. Prevalence, incidence, and outcomes of critical limb ischemia in the US medicare population. Vasc Dis Manag. 2013;10(2):26–36.
   Google Scholar
• Kalbaugh CA, Kucharska-Newton A, Wruck L, et al. Peripheral artery disease prevalence and incidence estimated from both outpatient and inpatient settings among medicare fee-for-service beneficiaries in the atherosclerosis risk in communities (ARIC) study. JAHA. 2017;6(5):e003796.
   Google Scholar
• Sridharan ND, Boitet A, Smith K, et al. Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. J Vasc Surg. 2018;67(1):343–352.
   PubMed Web of Science ®Google Scholar
• Mustapha JA, Katzen BT, Neville RF, et al. Determinants of long-term outcomes and costs in the management of critical limb ischemia: a population-based cohort study. JAHA. 2018;7(16):e009724.
   Google Scholar
• Henry J. Kaiser Family Foundation. Total number of Medicare beneficiaries. Available at https://www.kff.org/medicare/state-indicator/total-medicare-beneficiaries/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Accessed May 17, 2019.
   Google Scholar
• Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;69(11):e71–e126.
   PubMed Web of Science ®Google Scholar
• Fakhry F, Spronk S, van der Laan L, et al. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA. 2015;314(18):1936–1944.
   PubMed Web of Science ®Google Scholar
• Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am College Cardiol. 2015;65(10):999–1009.
   PubMed Web of Science ®Google Scholar
• Gray WA, Keirse K, Soga Y, on behalf of the IMPERIAL investigators, et al. A polymer-coated, paclitaxel-eluting stent (eluvia) versus a polymer-free, paclitaxel-coated stent (zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;392(10157):1541–1551.
   PubMed Web of Science ®Google Scholar
• Egorova NN, Guillerme S, Gelijns A, et al. An analysis of the outcomes of a decade of experience with lower extremity revascularization including limb salvage, lengths of stay, and safety. J Vasc Surg. 2010;51(4):878–885.
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial. Circulation. 2016;133(15):1472–1483.
   PubMed Web of Science ®Google Scholar
• Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78(4):611–617.
   PubMed Web of Science ®Google Scholar
• Iida O. Two-year outcomes from the IMPERIAL randomized trial of eluvia and zilver PTX. VIVA 2019. Nov 5, 2019, Las Vegas, NV, USA.
   Google Scholar
• Gray W. 2-year outcomes from the IMPERIAL randomized study of eluvia and zilver PTX. LINC 2020. Jan 28, 2020; Leipzig, Germany. https://linc2020.cncptdlx.com/media/1630_William_Gray_28_01_2020_Room_1_-_Main_Arena_1_v1.pdf
   Google Scholar
• Kearns BC, Thomas SM. Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study. BMJ Open. 2017;7(1):e013460.
   PubMed Web of Science ®Google Scholar
• Katsanos K, Geisler BP, Garner AM, et al. Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. BMJ Open. 2016;6(5):e011245.
   PubMed Web of Science ®Google Scholar
• Salisbury AC, Li H, Vilain KR, et al. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial. JACC Cardiovasc Interv. 2016;9(22):2343–2352.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Kearns B, Stevenson MD, et al. Enhancements to angioplasty for peripheral arterial occlusive disease: Systematic review, cost-effectiveness assessment and expected value of information analysis. Health Technol Assess. 2014;18(10):1–252.
   PubMed Web of Science ®Google Scholar
• Pietzsch JB, Geisler BP, Garner AM, et al. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv. 2014;84(4):546–554.
   PubMed Web of Science ®Google Scholar
• Kearns BC, Michaels JA, Stevenson MD, et al. Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease. Br J Surg. 2013;100(9):1180–1188.
   PubMed Web of Science ®Google Scholar
• Diehm N, Schneider H. Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions. J Endovasc Ther. 2013;20(6):819–825.
   PubMed Web of Science ®Google Scholar
• De Cock E, Sapoval M, Pierre J, et al. A budget impact model for paclitaxel-eluting stent in femoropopliteal disease in France. Cardiovasc Intervent Radiol. 2013;36(2):362–370.
   PubMed Web of Science ®Google Scholar
• https://treeage.zendesk.com/hc/en-us/articles/222718328-Simulations-in-TreeAge-Pro-Patient-Simulation-PSA-More.
   Google Scholar
• https://treeage.zendesk.com/hc/en-us/community/posts/115008171528-Understanding-Simulations-in-TreeAge-Pro.
   Google Scholar
• Barshes NR, Flores E, Belkin M, et al. The accuracy and cost-effectiveness of strategies used to identify peripheral artery disease among patients with diabetic foot ulcers. J Vasc Surg. 2016;64(6):1682–1690.
   PubMed Web of Science ®Google Scholar
• CPI Adjustment Table (hrsa.gov.)
   Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on Cost-Effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14(4):339–347.
   PubMed Web of Science ®Google Scholar